Funded Startups in Malvern
In Malvern, the largest disclosed funding amount in the 11 most recent entries is Aclaris Therapeutics at $80M (2024-11-18).
In Malvern, the largest disclosed funding amount in the 11 most recent entries is Aclaris Therapeutics at $80M (2024-11-18). That figure sits well above the rest of the disclosed rounds, where the next-largest disclosed amounts are $60M (Neuronetics, 2023-04-04) and $46M (TELA Bio, 2024-10-23), and multiple companies cluster at lower disclosed levels such as $45M (Savana, 2022-07-22) and $30M (Galera Therapeutics, 2023-02-15). An outlier also appears in the opposite direction: AKUVO (2025-09-21) is listed as undisclosed, so disclosed comparisons start from the $2M floor (Baudax Bio, 2023-08-17; Toetal Solutions, 2022-10-20).
The list is heavily weighted toward Biotechnology: 7 of 11 entries are categorized as Biotechnology (AKUVO, Ocugen, Aclaris Therapeutics, TELA Bio, Baudax Bio, Neuronetics, Galera Therapeutics, Venatorx Pharmaceuticals). Temporally, the rounds span from 2022-04-11 (Momentum Dynamics) to 2025-09-21 (AKUVO), with three of the biotech rounds landing within a tight late-2024 window (TELA Bio on 2024-10-23, Aclaris Therapeutics on 2024-11-18, and Ocugen on 2025-08-08 falls later). Overall, 9 of 11 entries carry a “Series Unknown” label, while 1 is explicitly “Seed” (Toetal Solutions, $2M) and 1 is explicitly “Debt Financing” (Momentum Dynamics, $8M).
Most recent rounds
11 shownRelated listings
Frequently asked
Which disclosed round is largest in this Malvern list, and how does it compare to the rest?
Aclaris Therapeutics’ $80M round (2024-11-18) is the top disclosed amount, with Neuronetics at $60M (2023-04-04) and TELA Bio at $46M (2024-10-23) trailing behind; several other disclosed rounds sit at $45M or below (Savana $45M on 2022-07-22; Galera Therapeutics $30M on 2023-02-15).
Do rounds concentrate in a specific time window, or are they spread evenly across the range shown?
They’re spread across 2022-04-11 (Momentum Dynamics) through 2025-09-21 (AKUVO), but there’s noticeable clustering in 2023–2024 among disclosed biotech rounds: Neuronetics ($60M, 2023-04-04), Galera Therapeutics ($30M, 2023-02-15), Baudax Bio ($2M, 2023-08-17), TELA Bio ($46M, 2024-10-23), and Aclaris Therapeutics ($80M, 2024-11-18).
Is Biotechnology over-represented versus other sectors in these 11 entries?
Yes. Biotechnology accounts for 8 of 11 entries (AKUVO, Ocugen, Aclaris Therapeutics, TELA Bio, Baudax Bio, Neuronetics, Galera Therapeutics, Venatorx Pharmaceuticals), while Financial Services appears 2 times (AKUVO; Savana) and Health Care appears 1 time (Toetal Solutions, Seed, $2M).
What stage labeling pattern stands out, and does it affect comparability across deals?
“Series Unknown” appears on 9 of the 11 entries (including major disclosed rounds like Aclaris Therapeutics $80M on 2024-11-18 and Neuronetics $60M on 2023-04-04). The remaining labels are Seed (Toetal Solutions, $2M on 2022-10-20) and Debt Financing (Momentum Dynamics, $8M on 2022-04-11), which concentrates most disclosed comparisons into the “unknown” bucket.
Are there notable outliers in disclosed size (high or low) that are worth focusing on?
On the high end, Aclaris Therapeutics’ $80M (2024-11-18) dwarfs most other disclosed amounts in the list, with the next-largest at $60M (Neuronetics, 2023-04-04). On the low end, the smallest disclosed amount is $2M, appearing for Baudax Bio (2023-08-17) and Toetal Solutions (2022-10-20), while AKUVO is the only entry marked undisclosed (2025-09-21).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.